Literature DB >> 26202566

Single Institution Experience with Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for the Primary Prevention of Lymphedema.

Sheldon Feldman1, Hannah Bansil, Jeffrey Ascherman, Robert Grant, Billie Borden, Peter Henderson, Adewuni Ojo, Bret Taback, Margaret Chen, Preya Ananthakrishnan, Amiya Vaz, Fatih Balci, Chaitanya R Divgi, David Leung, Christine Rohde.   

Abstract

BACKGROUND: As many as 40 % of breast cancer patients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic-venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009.
METHODS: LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve. Follow-up was with pre- and postoperative lymphoscintigraphy, arm measurements, and (L-Dex®) bioimpedance spectroscopy.
RESULTS: Over 26 months, 37 women underwent attempted LYMPHA, with successful completion in 27. Unsuccessful attempts were due to lack of a suitable vein (n = 3) and lymphatic (n = 5) or extensive axillary disease (n = 1). There were no LYMPHA-related complications. Mean follow-up time was 6 months (range 3-24 months). Among completed patients, 10 (37%) had a body mass index of ≥30 kg/m(2) (mean 27.9 ± 6.8 kg/m(2), range 17.4-47.6 kg/m(2)), and 17 (63%) received axillary radiotherapy. Excluding two patients with preoperative lymphedema and those with less than 3-month follow-up, the lymphedema rate was 3 (12.5%) of 24 in successfully completed and 4 (50 %) of 8 in unsuccessfully treated patients.
CONCLUSIONS: Our transient lymphedema rate in this high-risk cohort of patients was 12.5%. Early data show that LYMPHA is feasible, safe, and effective for the primary prevention of breast cancer-related lymphedema.

Entities:  

Mesh:

Year:  2015        PMID: 26202566     DOI: 10.1245/s10434-015-4721-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

Review 1.  Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.

Authors:  Sarah A McLaughlin; Cheryl L Brunelle; Alphonse Taghian
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

Review 2.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

Authors:  Tessa C Gillespie; Hoda E Sayegh; Cheryl L Brunelle; Kayla M Daniell; Alphonse G Taghian
Journal:  Gland Surg       Date:  2018-08

Review 3.  Outcomes of Lymphovenous Anastomosis for Upper Extremity Lymphedema: A Systematic Review.

Authors:  Nikita Gupta; Erik M Verhey; Ricardo A Torres-Guzman; Francisco R Avila; Antonio Jorge Forte; Alanna M Rebecca; Chad M Teven
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-08-25

4.  Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Prevention of Breast Cancer-Related Lymphedema-a Preliminary Report.

Authors:  Juhi Agrawal; Sandeep Mehta; Ashish Goel; Pankaj Kumar Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2018-02-17

5.  Aligned nanofibrillar collagen scaffolds - Guiding lymphangiogenesis for treatment of acquired lymphedema.

Authors:  Stanley G Rockson; John P Cooke; Ngan F Huang; Catarina Hadamitzky; Tatiana S Zaitseva; Magdalena Bazalova-Carter; Michael V Paukshto; Luqia Hou; Zachary Strassberg; James Ferguson; Yuka Matsuura; Rajesh Dash; Phillip C Yang; Shura Kretchetov; Peter M Vogt
Journal:  Biomaterials       Date:  2016-06-07       Impact factor: 12.479

6.  Lymphatic mapping and preoperative imaging in the management of post-mastectomy lymphoedema.

Authors:  Muhammed Chowdhry; Warren Matthew Rozen; Matthew Griffiths
Journal:  Gland Surg       Date:  2016-04

7.  Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.

Authors:  Kelly M Herremans; Morgan P Cribbin; Andrea N Riner; Dan W Neal; Tracy L Hollen; Pamela Clevenger; Derly Munoz; Shannon Blewett; Fantine Giap; Paul G Okunieff; Nancy P Mendenhall; Julie A Bradley; William M Mendenhall; Raymond B Mailhot-Vega; Eric Brooks; Karen C Daily; Coy D Heldermon; Julia K Marshall; Mariam W Hanna; Mark M Leyngold; Sarah S Virk; Christiana M Shaw; Lisa R Spiguel
Journal:  Ann Surg Oncol       Date:  2021-08-07       Impact factor: 5.344

8.  Survivorship and Advocacy in Inflammatory Breast Cancer.

Authors:  Angela Alexander; Terry Lynn Arnold; Sandra Bishnoi; Caroline Ballinger; Simona F Shaitelman; Mark V Schaverien; Lorenzo Cohen; Mary Dev; Naoto T Ueno
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

9.  Controversies in Surgical Management of Lymphedema.

Authors:  Summer E Hanson; Edward I Chang; Mark V Schaverien; Carrie Chu; Jesse C Selber; Matthew M Hanasono
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-27

10.  Building a Multidisciplinary Comprehensive Academic Lymphedema Program.

Authors:  Mark V Schaverien; Donald P Baumann; Jesse C Selber; Edward I Chang; Matthew M Hanasono; Carrie Chu; Summer E Hanson; Charles E Butler
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.